BeyondSpring Inc. (BYSI) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research cut shares of BeyondSpring Inc. (NASDAQ:BYSI) from a hold rating to a sell rating in a research report sent to investors on Monday morning.

According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “

Other research analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a buy rating and set a $50.00 target price on shares of BeyondSpring in a research note on Monday, August 21st. Maxim Group reaffirmed a buy rating and set a $52.00 target price on shares of BeyondSpring in a research note on Friday, October 27th.

Shares of BeyondSpring (BYSI) traded down $0.68 during mid-day trading on Monday, reaching $34.83. The company had a trading volume of 1,000 shares, compared to its average volume of 5,758. BeyondSpring has a fifty-two week low of $16.55 and a fifty-two week high of $48.49.

BeyondSpring (NASDAQ:BYSI) last announced its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. equities analysts forecast that BeyondSpring will post -4.41 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://transcriptdaily.com/2017/11/14/beyondspring-inc-bysi-downgraded-to-sell-at-zacks-investment-research.html.

An institutional investor recently bought a new position in BeyondSpring stock. Tanaka Capital Management Inc. purchased a new stake in BeyondSpring Inc. (NASDAQ:BYSI) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring accounts for approximately 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th biggest position. Tanaka Capital Management Inc. owned 0.10% of BeyondSpring as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 1.23% of the company’s stock.

BeyondSpring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply